Friday, May 01, 2020 12:03:37 PM
The distinction between 'Clinical Trials' and 'Device testing' is very important here.
The FDA PREFERS clinical trial data to come from the population in which the treatment is to be deployed.
Clinical trials determine the safety and efficacy of a new treatment. And the FDA want to know for instance that a treatment which was safely administered to lithe Japanese subjects with a BMI of 22 will not be harmful when dosed out to corpulent Americans with a BMI of 28. Which is why they prefer US trial data. They will accept trial data from anywhere so long as it satisfactorily answers the question "How will this treatment play out on my US population?" The easiest way to do this, of course, is to do the trials ON the US population.
Diagnostics Device testing is different. Device testing is NOT a clinical trial. It is a validation/ verification activity.
The damn thing either works or it doesn't.
The FDA want evidence that the device is safe and effective. They don't care where geographically that data came from, as long as it is robust, validated and verifiable i.e. produced to the right scientific standard.
Its A bullshit excuse. Berman does not have Korean data that would satisfy the FDA, if it had been done in a US lab. If he did, he'd submit it.
If he HAS any data, its not the fact that it is Korean that would trouble the FDA. Its the fact that it wouldn't satisfactorily address the required claims.
Don't take my word for it. Go look on the FDA website. Its full of 510K submissions and device testing from international labs being used to clear diagnostics devices into US markets. Heave a brick, hit a dozen.
FEATURED Key Metals Surge, Unlocking New Opportunities for Savvy Mining Investors • Nov 19, 2024 8:45 AM
FEATURED Greenlane Signs New U.S. Distribution Agreement with Veriteque USA, Manufacturer of the SwabTek™ and Verifique™ Brand of Field Test Kits • Nov 19, 2024 8:34 AM
FEATURED Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • Nov 18, 2024 11:56 AM
Geo-Political Tensions and Trump's Increasing Military Budgets Could Boost Demand for Actelis' Cyber Hardened Networking Tech ($ASNS) • ASNS • Nov 19, 2024 10:24 AM
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis Dispensary • CBDL • Nov 19, 2024 8:00 AM
North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • NBRI • Nov 18, 2024 9:00 AM